Proteomics

Dataset Information

0

Disruption of the ALK tumor cell proteome by concurrent inhibation of ALK and SRC kinases


ABSTRACT: Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, refractory tumors with compound mutations or diverse resistance mechanisms remain an unmet clinical need. In this study, we established mouse tumor-derived cell models representing the most common EML4-ALK variants in human lung adenocarcinomas and characterized their proteomic profiles. We demonstrated that Eml4-Alk variant 3 confers a worse response to ALK inhibitors, suggesting its role in promoting resistance. In addition, proteomic analysis of brigatinib-treated cells revealed the upregulation of SRC kinase, which is frequently activated in cancer. Co-targeting of ALK and SRC showed remarkable inhibitory effects on both ALK-driven murine tumor growth and ALK-patient-derived cells. This death mechanism is attributed to the profound perturbation of the (phospho)proteomic landscape, together with a synergistic suppressive effect on the mTOR pathway. Taken together, our study identifies the inhibition of ALK and SRC cells and may offer a promising strategy to overcome resistance mechanisms and improve clinical outcomes in ALK-positive lung cancer patients.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Culture

DISEASE(S): Non-small Cell Lung Carcinoma

SUBMITTER: Marcel Schilling  

LAB HEAD: Prof. Ursula Klingmüller

PROVIDER: PXD042728 | Pride | 2024-04-11

REPOSITORIES: Pride

altmetric image

Publications

Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.

Diaz-Jimenez Alberto A   Ramos Maria M   Helm Barbara B   Chocarro Sara S   Frey Dario Lucas DL   Agrawal Shubham S   Somogyi Kalman K   Klingmüller Ursula U   Lu Junyan J   Sotillo Rocio R  

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20240319


Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, an unmet clinical need still to address is the treatment of refractory tumors that contain drug-induced resistant mutations in the driver oncogene or exhibit resistance through the activation of diverse mechanisms. In this study, we established mouse tumor-derived cell models representing the two most prevalent EML4-ALK variants in human lung adenocarcinomas and characterized their p  ...[more]

Similar Datasets

2024-04-11 | PXD043012 | Pride
2022-12-18 | E-MTAB-11304 | biostudies-arrayexpress
2021-05-20 | GSE174772 | GEO
2021-01-20 | GSE165137 | GEO
2019-12-15 | E-MTAB-8563 | biostudies-arrayexpress
2019-12-22 | E-MTAB-8590 | biostudies-arrayexpress
2021-05-19 | GSE174596 | GEO
2022-11-05 | GSE217115 | GEO
2019-12-31 | GSE117181 | GEO
2014-07-14 | GSE49508 | GEO